Guideline publication synthesizes evidence for clinical practice recommendations.

The U.S. Food and Drug Administration released in January 2026 a draft guidance on the use of Bayesian methodology in clinical trials of drugs and biological products, representing a significant evolution in its regulatory approach to evaluating evidence supporting marketing authorization. The guidance reflects a growing consensus in regulatory science that traditional frequentist clinical efficacy trials, particularly equivalence and non-inferiority designs, are often poorly aligned with the scientific questions regulators must answer, mainly when substantial prior knowledge exists. This review examines the scientific literature questioning the value of routine clinical efficacy testing, with particular emphasis on biosimilars, and explains how Bayesian inference provides a coherent framework for integrating analytical, pharmacokinetic, clinical, and real-world evidence. The article analyzes the structure and reasoning of the FDA's new guidance, showing how it formalizes a justification-first approach to clinical testing and has potential implications beyond biosimilars, particularly where prior evidence is strong. The review addresses both the advantages and limitations of Bayesian regulatory applications, including potential failure modes and necessary safeguards. Finally, the broader implications of Bayesian regulatory decision-making for drug development efficiency, ethical standards, and global regulatory harmonization are discussed.